ABSTRACT A discrete population of cells of the endocrine pancreas contains immunoreactive somatostatin as shown by immunofluorescence. These cells are different from those containing glucagon or insulin. This unexpected observation may be of physiopathological significance in the regulatory mechanisms involved in the secretion of glucagon and insulin.
Somatostatin is an oligopeptide with the primary sequence isolated from ovine hypothalamic extracts (1) on the basis of its activity to inhibit the secretion of adenohypophysial growth hormone (2, 3) . Availability of the peptide in large quantities obtained by total synthesis (4) has shown it to be biologically active, both in the cyclized (oxidized) or linear (reduced) form, to inhibit the secretion of growth hormone in all the species studied so far. Recently, it has been shown that somatostatin also inhibits the secretion of glucagon and insulin (5) by acting directly at the level of the cells of the endocrine pancreas (5) (6) (7) .
Furthermore, on the basis of bioassays, somatostatin or somatostatin-like substances have been shown to have a large extra-hypothalamic distribution in the central nervous system (8) . This set of observations, combined with the evidence of a very short (<4 min) biological half-life for somatostatin upon intravenous injection, led to the hypothesis that the peptide might be delivered to the endocrine cells of the pancreas by peripheral nerves with peptidergic endings. This was explored by immunohistochemistry, a method which had previously led to localize (immunoreactive) somatostatin in the median eminence (9) (10) (11) as well as in discrete nerve fibers in the pars tuberalis (11) . The results reported here* will show that, contrary to expectations, no nerve fibers oi endings containing immunoreactive somatostatin were found in the pancreas of the several species studied; unexpectedly, however, a definite population of cells in the islets of Langerhans was found to contain immunoreactive somatostatin.
MATERIALS AND METHODS
(a) Production of Antisera to Somatostatin. Somatostatin and its reduced form, H2 somatostatin, were coupled to human serum albumin with glutaraldehyde or bisdiazotized benzidine. The complexed antigen was injected with adjuvant into rabbits. A detailed description of the immunization procedure has been published previously (11) . Only animals injected with the oxidized form of somatostatin yielded detectable antibodies. The antiserum used here is our lot no. 1251. No immunofluorescence reaction was seen in the endocrine pancreas of any of the six species studied with the antiserum against gastrin, while the reaction was extremely intense in cells of the j uxtapyloric regions of (rat) gastric mucosa.
Specificity of the immunofluorescence reactions
Somatostatin. It has been demonstrated and reported elsewhere (11) that the antiserum to somatostatin used here does not bind any of the following neuropeptides: neurophysin-A, oxytocin, [Arg8]vasopressin, luteinizing hormone releasing factor, and thyrotropin releasing factor. In the studies reported here, none of these peptides inhibit the immunocytological binding of the somatostatin-antiserum to the pancreatic cells described above. Similarly, glucagon, insulin, secretin, and the tetrapeptide Thr-Phe-Thr-Ser (common to somatostatin, glucagon and secretin) do not interfere with the immunocytological binding of the somatostatin-antiserum, in concentrations up to 32 mg of peptide per ml of nondiluted antiserum. Only somatostatin in either the oxidized or reduced form inhibits the immunofluorescence reaction due to the somatostatin-antiserum.
Insulin, Glucagon. None of the polypeptides listed above inhibit the immunofluorescence reaction due to insulinantiserum, except insulin itself. Glucagon and secretin (which share a large degree of homology in terms of charge and polarity of amino-acid sequences) (13) Immunoreactive somatostatin is not observed by the method described here in any of the other organs or tissues listed above.
DISCUSSION
None of the many peptides listed above, with the exception of somatostatin itself, inhibits the antigen-antibody reaction obtained with somatostatin-antiserum. Thus, with the caveat that must prevail when considering results obtained by immunocompetence, we will assume that the antigen characterized by the immunocytological procedure is somatostatin. In favor of this assumption is the recent observation of bioassayable somatostatin-activity in aqueous extracts of (rat) fetal pancreas (14) .
The presence of cells containing somatostatin in the islets of the pancreas of all species studied is a totally unexpected observation, with possibly far-reaching significance in terms of the physiological mechanisms it evokes regarding secretion of glucagon and insulin. The statement relates to the now well-authenticated effect of exogenously administered somatostatin as an inhibitor of the secretion of both glucagon and insulin by direct action at some receptor site on both the a2-and,3-cells of the endocrine pancreas. Due to the absence of sensitive assay for measuring somatostatin in small volumes of body fluids, nothing is known at the moment of the dynamics of the secretion of hypothalamic somatostatin; nor is it known whether somatostatin is present in peripheral blood and, if it is at all, if it is in variable amounts as a function of corresponding physiological situations. In view of the very short biological half life of exogenously administered somatostatin, for somatostatin of hypothalamic origin to have a regulatory role at the level of the endocrine pancreas one can easily calculate that unusually high levels of the hypothalamic peptide should be secreted to maintain peripheral concentrations high enough to exert a regulatory effect at the level of the endocrine pancreas. Thus, observing the presence of cells containing somatostatin within the endocrine islets of the pancreas suggests that these may be part of a peripheral regulatory mechanism involving (pancreatic) somatostatin 
